NCT01242930已完成2 期
A Phase II Trial to Determine the Effect of Imetelstat (GRN163L) on Patients With Previously Treated Multiple Myeloma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 13
- 试验地点
- 4
- 主要终点
- Rate of Improvement in Response
研究概览
简要总结
This is an open label Phase II study to determine the rate of improvement in response of patients with previously treated multiple myeloma to imetelstat alone or in combination with lenalidomide maintenance therapy. This study will include multiple myeloma patients who either have achieved disease stabilization or who have achieved at least a partial response (PR) but failed to achieve a complete response (CR) after cytoreductive therapy for multiple myeloma; ie, have detectable but non-progressing disease and will most likely relapse.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to sign an informed consent Male or female, 18 years or older Confirmed diagnosis of multiple myeloma (secretory disease) by International Myeloma Working Group Diagnostic Criteria
- •Patients must meet one of the following criteria:
- •o Previously treated patients with multiple myeloma who achieved at least stable disease but who have failed to achieve a complete response (CR) after a minimum of one cytoreductive therapy for multiple myeloma and have detectable but non-progressing disease. Patients must have received at least one proteasome inhibitor (eg, bortezomib) or one immunomodulatory agent (eg, thalidomide or lenalidomide) or both.
- •Patients receiving lenalidomide as maintenance therapy may continue to receive this therapy provided that the patient has been on this maintenance therapy for a minimum of 3 months and has evidence of disease stabilization.
- •Disease stabilization will be defined as an M protein that varies ≤ 25% over the three measurements or remains under 0.5 g/dL whichever is smaller.
- •ECOG performance status 0-2 Life expectancy ≥ 3 months
- •Laboratory criteria (within 14 days of first study drug administration):
- •ANC ≥ 1000/μL
- •Platelet count ≥ 50 x 103/μL (without transfusion support within 2 weeks prior to first study drug administration)
- •Hemoglobin ≥ 8.0 g/dL
- •Serum creatinine ≤ 3 x the upper limit of normal (ULN)
- •AST (SGOT) and ALT (SGPT) ≤ 2.5 x the upper limit of normal (ULN), unless due to disease.
- •Must have fully recovered from any previous cancer treatments and/or major surgery.
- •Women of childbearing potential must have a negative serum pregnancy test and agree to use effective birth control (two reliable forms of contraception) during and for at least 12 weeks after the last treatment.
- •Males must agree to use effective birth control for themselves or their partner during and for 12 weeks after the last treatment with imetelstat. For those patients receiving lenolidomide, males must use latex condom during sexual contact with women of childbearing potential even if they have undergone a successful vasectomy.
排除标准
- •Women who are pregnant or breast feeding Prior radioimmunotherapy. Known intracranial disease or epidural disease. Patients with lytic lesions of the cranium or spine secondary to myeloma are eligible to enroll.
- •Clinically significant cardiovascular disease or condition including:
- •Congestive heart failure (CHF) requiring therapy
- •Need for antiarrhythmic therapy for a ventricular arrhythmia
- •Severe conduction disturbance
- •Angina pectoris requiring therapy
- •Uncontrolled hypertension per the Investigator's discretion
- •New York Heart Association Class II, III, or IV cardiovascular disease Active or chronically recurrent bleeding (eg, active peptic ulcer disease) Clinically relevant active infection. Serious co-morbid medical conditions, including cirrhosis and chronic obstructive or chronic restrictive pulmonary disease.
- •Symptomatic hyperviscosity syndrome. Any other cancer therapy including chemotherapy, monoclonal antibody, signal transduction inhibitor, immunotherapy, glucocorticoid (except topical or as premedication), thalidomide within 3 weeks prior to first study drug administration.
- •Investigational therapy within 4 weeks prior to first study drug administration.
- •Major surgery within 4 weeks prior to first study drug administration (central line placement is allowed) Anti-platelet therapy within 2 weeks prior to first study drug administration, other than low dose aspirin prophylaxis therapy.
- •Full dose anticoagulation. Prophylactic low dose administration for management of IV access devices is allowed.
- •Known positive serology for human immunodeficiency virus (HIV. Any other severe, acute, or chronic medical or psychiatric condition, laboratory abnormality, or difficulty complying with protocol requirements that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for this study
研究组 & 干预措施
Imetelstat (9.4 mg/kg)
Experimental
Imetelstat (9.4 mg/kg) with or without lenalidomide standard of care
干预措施: Imetelstat (9.4 mg/kg) (Drug)
Imetelstat (7.5 mg/kg)
Experimental
Imetelstat (7.5 mg/kg) with or without lenalidomide standard of care
干预措施: lenalidomide standard of care (Drug)
Imetelstat (9.4 mg/kg)
Experimental
Imetelstat (9.4 mg/kg) with or without lenalidomide standard of care
干预措施: lenalidomide standard of care (Drug)
Imetelstat (7.5 mg/kg)
Experimental
Imetelstat (7.5 mg/kg) with or without lenalidomide standard of care
干预措施: Imetelstat (7.5 mg/kg) (Drug)
结局指标
主要结局
Rate of Improvement in Response
时间窗: From time of first dose (Cycle 1 day 1) through end of study period (12 mos. after last participant is enrolled)
To determine the rate of improvement in response in patients with previously treated multiple myeloma following treatment with imetelstat alone or in combination wtih lenalidomide maintenance therapy. Response will be assessed using the International Uniform Response Criteria for Multiple Myeloma (IURCMM).
次要结局
- Safety and Tolerability(From time of first dose (Cycle 1 day 1) through end of study (12 mos. after last participant is enrolled))
- Progression-free Survival (PFS)(From time of first dose (Cycle 1 day 1) through end of study (12 mos. after last participant is enrolled))
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia VeraPolycythemia VeraEssential ThrombocythemiaNCT01243073Geron Corporation20
招募中
1 期
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant TumorsAdvanced Malignant TumorsNCT06223841SUNHO（China）BioPharmaceutical CO., Ltd.50
已完成
2 期
A phase IIb, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple subcutaneous doses of BMN 045 (previously known as PRO045) in subjects with Duchenne muscular dystrophyDuchenne's disease1002830210029317Duchenne muscular dystrophyNL-OMON43779BioMarin Parmaceutical Inc.5
进行中（未招募）
1 期
A study to test if multiple injections of PRO045 are safe and effective in people who suffer from Duchenne muscular dystrophyDuchenne muscular dystrophy resulting from a mutation correctable by PRO045-induced DMD exon 45 skippingMedDRA version: 18.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-005040-10-FRProsensa Therapeutics BV45
进行中（未招募）
1 期
A study to test if multiple injections of PRO045 under the skin are safe and effective in people who suffer from Duchenne muscular dystrophyDuchenne muscular dystrophy resulting from a mutation correctable by PRO045-induced DMD exon 45 skippingMedDRA version: 18.1Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-005040-10-BEBioMarin Nederland B.V.45